NasdaqGS:ARQTBiotechs
Arcutis ZORYVE Infant Data Adds New Dimension To Atopic Dermatitis Thesis
Arcutis Biotherapeutics reported positive Phase 2 topline results for ZORYVE cream in infants with atopic dermatitis.
The study focused on a vulnerable pediatric group that currently has limited treatment options.
For investors watching Arcutis Biotherapeutics, NasdaqGS:ARQT, the latest ZORYVE update adds new context to a share price of $26.07. The stock has returned 109.9% over the past year and 57.7% over the past 3 years, while the 5 year return stands at a 25.1% decline. Short term...